Insmed announced that adult patient enrollment is complete as of today in its pivotal ASPEN study of brensocatib. Insmed anticipates reporting topline data from adults in the ASPEN trial in the second quarter of 2024.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INSM: